A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer
| العنوان: | A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer |
|---|---|
| المؤلفون: | Abramson V, Oliveira M, Cervantes A, Wildiers H, Patel M, Bauer T, Bedard P, Becerra C, Richey S, Wei M, Reyner E, Bond J, Cui N, Wilson T, Moore H, Saura C, Krop I |
| المصدر: | BREAST CANCER RESEARCH AND TREATMENT r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA instname |
| بيانات النشر: | SPRINGER, 2019. |
| سنة النشر: | 2019 |
| تدمد: | 0167-6806 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::e1ef52eb712a0bc75c21f04457f43565 https://www.fundanet.incliva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=3950 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.RECOLECTA.....e1ef52eb712a0bc75c21f04457f43565 |
| قاعدة البيانات: | OpenAIRE |
Find this article in full text from Springer Verlag. | تدمد: | 01676806 |
|---|